Pamela Spicer @Datamonitor_PS

Analyst | Autoimmune & Inflammation | CNS | Views & opinions expressed are strictly my own Joined September 2014

Tweets

522
Followers

190
Following

351
Likes

12

Mandy Jackson @ScripMandy

4 years ago

$LLY Floated the idea of some kind of accelerated approval for its injectable donanemab earlier this year but has since backed off of that. Will that change now that $BIIB has been granted accelerated approval for infused antibody Aducanumab based on amyloid-clearing activity?

2 3 10 0 0

Mandy Jackson @ScripMandy

4 years ago

While we await a decision on $BIIB Aducanumab In Alzheimer’s disease, @PinkSheetSutter took a look at other controversial FDA approvals.

Derrick @dgingery

4 years ago

While we await a decision on $BIIB Aducanumab In Alzheimer’s disease, @PinkSheetSutter took a look at other controversial FDA approvals.

1 1 2 0 0

0 1 1 0 0

Pamela Spicer @Datamonitor_PS

4 years ago

$BMY declares deucravacitinib as first in new TYK2-selective class to differentiate from JAKs #AADVMX2021 s21.q4cdn.com/104148044/file…

0 1 1 0 0

Pamela Spicer @Datamonitor_PS

5 years ago

Aducanumab AdComm panel disagrees with FDA about strong evidence of effectiveness provided by the positive study

0 0 1 0 0

Sue Sutter @PinkSheetSutter

5 years ago

Alzheimer's Association rep urges approval, says requiring another Ph III trial would delay access to #aducanumab for 4 years; urges panel to weigh the scientific uncertainty against the certainty of what disease will do to millions of people

0 2 3 0 0

Pamela Spicer @Datamonitor_PS

5 years ago

Aducanumab AdComm open public hearing: patients comment on rapid decline 6-8 months after stopping treatment.

0 1 3 0 0

Pamela Spicer @Datamonitor_PS

5 years ago

Aducanumab AdComm - In response to Dr. Joel Perlmutter’s question on dose response, @US_FDA confirms there is a sub-set of ENGAGE patients who are inconsistent with EMERGE, and not consistent with what would be expected in a dose-response relationship

1 1 2 0 1

Pamela Spicer @Datamonitor_PS

5 years ago

FDA AdComm - In replying to to Dr. Chiadi Onyike’s question on differences in placebo response between the aducanumab studies $BIIB said greater decline on CDR in EMERGE played a minor role in explaining differences in EMERGE’s positive outcome vs the negative topline from ENGAGE

0 0 1 0 0

Pamela Spicer @Datamonitor_PS

5 years ago

$BIIB say only high dose is discordant between aducanumab's ENGAGE/EMERGE in response to Dr. Caleb Alexander's concern about the "extraordinary amount of explaining" about the data

0 0 1 0 0

Sue Sutter @PinkSheetSutter

5 years ago

Still early on in #aducanumab AdComm, but fair to say biostatistican Scott Emerson, a temporary voting member, is highly skeptical of the efficacy analyses and explanation of differences b/n the two studies ...

0 4 7 0 0

Pamela Spicer @Datamonitor_PS

5 years ago

$BIIB: amyloid testing for treatment with aducanumab may not necessarily be limited to PET testing as it was in the study

0 0 2 0 0

Pamela Spicer @Datamonitor_PS

5 years ago

Outlook For Biogen's Aducanumab Brightens Based On FDA Clues scrip.pharmaintelligence.informa.com/articles/2020/…

0 0 0 0 0

Pamela Spicer @Datamonitor_PS

5 years ago

Nov 6 FDA AdCom briefing documents for $BIIB aducanumab in early #Alzheimer’s released fda.gov/advisory-commi…

0 0 0 0 0

Pamela Spicer @Datamonitor_PS

5 years ago

Limited details, but topline H2H Ph3 suggests $BMY was right to divest Otezla to $AMGN in favor of TYK2i in oral #psoriasis showdown news.bms.com/news/corporate…

0 0 0 0 0

Pamela Spicer @Datamonitor_PS

6 years ago

TRIAD-2, second Phase 3 trial of AVP-786 for agitation in Alzheimer's, fails to meet primary endpoint otsuka.co.jp/en/company/new…

0 0 0 0 0

Pamela Spicer @Datamonitor_PS

6 years ago

$LLY data confirm shorter-term IL-17 > IL-23 in #psoriasis , but what about longer-term results? TBD in 2020 investor.lilly.com/news-releases/…

0 0 0 0 0

Citeline @Citeline

6 years ago

Are you ready for our first #twitterchat? First a few house rules: ✅Start your post with Q: ✅Always use the hashtag #AskTheAnalyst ✅Tag @Pharma_Intell in your post Follow these & we will be able to see all your questions. We look forward to chatting with you!

0 3 3 0 0

Download Image

Citeline @Citeline

6 years ago

Will you be ready to #asktheanalyst on Wednesday, May 1st? We will be hosting our first #Twitterchat next week & our expert analysts are ready & waiting to answer your questions about the #pharma & #medtech industries. See you next week on @pharma_intell #asktheanalyst